Karyopharm Therapeutics Inc. (KPTI) SVP Christopher Brett Primiano Sells 4,958 Shares

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) SVP Christopher Brett Primiano sold 4,958 shares of the company’s stock in a transaction on Tuesday, November 7th. The stock was sold at an average price of $11.25, for a total transaction of $55,777.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Christopher Brett Primiano also recently made the following trade(s):

  • On Monday, October 2nd, Christopher Brett Primiano sold 1,500 shares of Karyopharm Therapeutics stock. The stock was sold at an average price of $12.00, for a total transaction of $18,000.00.
  • On Friday, September 15th, Christopher Brett Primiano sold 2,000 shares of Karyopharm Therapeutics stock. The stock was sold at an average price of $11.00, for a total transaction of $22,000.00.
  • On Tuesday, August 29th, Christopher Brett Primiano sold 2,195 shares of Karyopharm Therapeutics stock. The stock was sold at an average price of $10.00, for a total transaction of $21,950.00.

Karyopharm Therapeutics Inc. (KPTI) traded up $0.14 during midday trading on Friday, hitting $10.91. 96,148 shares of the stock were exchanged, compared to its average volume of 244,347. Karyopharm Therapeutics Inc. has a 1 year low of $7.48 and a 1 year high of $14.63.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its earnings results on Thursday, November 2nd. The company reported ($0.65) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by ($0.01). Karyopharm Therapeutics had a negative net margin of 67,267.47% and a negative return on equity of 76.83%. analysts predict that Karyopharm Therapeutics Inc. will post -2.58 EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece was posted by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at https://transcriptdaily.com/2017/11/11/karyopharm-therapeutics-inc-kpti-svp-christopher-brett-primiano-sells-4958-shares.html.

Several institutional investors have recently modified their holdings of the stock. JPMorgan Chase & Co. raised its holdings in shares of Karyopharm Therapeutics by 753.5% during the third quarter. JPMorgan Chase & Co. now owns 307,200 shares of the company’s stock worth $3,342,000 after purchasing an additional 271,208 shares during the last quarter. Candriam Luxembourg S.C.A. increased its holdings in Karyopharm Therapeutics by 16.4% in the third quarter. Candriam Luxembourg S.C.A. now owns 510,000 shares of the company’s stock valued at $5,600,000 after buying an additional 72,000 shares in the last quarter. Nationwide Fund Advisors increased its holdings in Karyopharm Therapeutics by 396.0% in the third quarter. Nationwide Fund Advisors now owns 105,664 shares of the company’s stock valued at $1,160,000 after buying an additional 84,362 shares in the last quarter. California State Teachers Retirement System increased its holdings in Karyopharm Therapeutics by 12.2% in the second quarter. California State Teachers Retirement System now owns 59,844 shares of the company’s stock valued at $542,000 after buying an additional 6,500 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its holdings in Karyopharm Therapeutics by 26.2% in the second quarter. The Manufacturers Life Insurance Company now owns 26,907 shares of the company’s stock valued at $243,000 after buying an additional 5,586 shares in the last quarter. 59.14% of the stock is owned by hedge funds and other institutional investors.

Several brokerages recently weighed in on KPTI. ValuEngine raised shares of Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 24th. Robert W. Baird reissued a “buy” rating on shares of Karyopharm Therapeutics in a report on Friday, November 3rd. BidaskClub raised shares of Karyopharm Therapeutics from a “strong sell” rating to a “sell” rating in a report on Wednesday, August 9th. Jefferies Group LLC restated a “buy” rating on shares of Karyopharm Therapeutics in a research report on Friday, October 13th. Finally, Zacks Investment Research lowered shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, July 18th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $15.50.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Insider Buying and Selling by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply